A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours

被引：4
|
作者：
Luke, J. J. [1 ]
Janku, F. [2 ]
Strauss, J. [3 ]
Olszanski, A. J. [4 ]
Leach, K. [5 ]
Radhakrishnan, I. [5 ]
Abbas, A. [5 ]
机构：
[1] UPMC Hillman Canc Ctr, Med, Pittsburgh, PA USA
[2] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[3] Mary Crowley Med Res Ctr, Oncol, Dallas, TX USA
[4] Fox Chase Canc Ctr, Med Oncol, Main Campus, Philadelphia, PA 19111 USA
[5] Spring Bank Pharmaceut, Oncol Dept, Hopkinton, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.712
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
598TiP
引用
收藏
页码：S500 / S500
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [32] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [33] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [34] A phase I dose-escalation study of weekly multiple dose intravenously administered SR271425 in patients with refractory solid tumors.
    Calvo, E
    Lockhart, AC
    Tolcher, AW
    Rowinsky, EK
    Shackleton, G
    Morrison, JG
    Rafi, R
    Rothenberg, ML
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 215S - 215S
  • [35] A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
    Falchook, Gerald Steven
    Luke, Jason J.
    Strauss, James F.
    Gao, Xin
    LoRusso, Patricia
    Voon, Pei Jye
    Li, Cong
    Shaw, Michael
    Gregory, Richard C.
    Horn, Kristin
    Gibbs, John
    Lineberry, Neil
    Stumpo, Kate
    Malek, Karim
    Olszanski, Anthony J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Jordan Berlin
    Ramesh K. Ramanathan
    John H. Strickler
    Deepa S. Subramaniam
    John Marshall
    Yoon-Koo Kang
    Robert Hetman
    Matthew W. Dudley
    Jiewei Zeng
    Caroline Nickner
    Hao Xiong
    Philip Komarnitsky
    Stacie Peacock Shepherd
    Herbert Hurwitz
    Heinz-Josef Lenz
    British Journal of Cancer, 2018, 118 : 938 - 946
  • [37] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deepa S.
    Marshall, John
    Kang, Yoon-Koo
    Hetman, Robert
    Dudley, Matthew W.
    Zeng, Jiewei
    Nickner, Caroline
    Xiong, Hao
    Komarnitsky, Philip
    Shepherd, Stacie Peacock
    Hurwitz, Herbert
    Lenz, Heinz-Josef
    BRITISH JOURNAL OF CANCER, 2018, 118 (07) : 938 - 946
  • [38] A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer
    Nasim, Muhammad Yaser
    Plummer, Ruth
    Evans, T. R. Jeffry
    Morrison, Rosemary
    Anthoney, David Alan
    Haney, Sophie
    Madi, Ayman
    Savulsky, Claudio Isaac
    Johnston, Claire
    Carter, David
    Reyderman, Larisa
    Gopalakrishna, Prashanth
    Wanders, Jantien
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
    W S Siegel-Lakhai
    A S Zandvliet
    A D R Huitema
    M M Tibben
    G Milano
    V Girre
    V Diéras
    A King
    E Richmond
    J Wanders
    J H Beijnen
    J H M Schellens
    British Journal of Cancer, 2008, 98 : 1320 - 1326
  • [40] A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
    Siegel-Lakhai, W. S.
    Zandvliet, A. S.
    Huitema, A. D. R.
    Tibben, M. M.
    Milano, G.
    Girre, V.
    Dieras, V.
    King, A.
    Richmond, E.
    Wanders, J.
    Beijnen, J. H.
    Schellens, J. H. M.
    BRITISH JOURNAL OF CANCER, 2008, 98 (08) : 1320 - 1326
12345